Autres langues Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R3030

Temps Différé Nasdaq Autres places de cotation 19:39:02 08/05/2024			Varia. 5j.	Varia. 1 janv.
1,775 ^USD	-0,84 %		-4,57 %	+2,01 %

11/03	Les traders anticipent le rapport sur l'inflation alors que les actions américaines ouvrent en baisse à Wall Street	MT
11/03	Les plus fortes hausses du prémarché	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference	03/05
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting	20/03
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11/03
Top Premarket Gainers	11/03
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	11/03
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers	01/03
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update	15/02
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	14/02
North American Morning Briefing : Stock Futures -2-	09/02
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy	22/12
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update	15/12
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	14/12
North American Morning Briefing : Traders Await -2-	13/12
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering	26/10/23
Sector Update: Health Care Stocks Retreating Late Afternoon	25/10/23
Top Midday Decliners	25/10/23
Top Premarket Decliners	25/10/23
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society Annual Meeting	18/10/23
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology	21/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sonnet BioTherapeutics Holdings, Inc.

Actions

SONN

US83548R3030

Autres langues

Filtres